Daewoong Pharmaceutical Indonesia

Daewoong Urges ‘Sustained Lowering’ of Bad Cholesterol to Prevent Heart Attack and Stroke

Writer

Manager

December 9, 2025

- Health talk show held for high‑risk cardiovascular patients, highlighting the importance of LDL‑C control and treatment strategies

- “Lower LDL‑C, better prevention”—addressed causes of treatment failure and introduced combination therapy for sustainable management

- “I thought treatment was finished once I reached my target LDL‑C… but now I realized continuous management is essential,” said one patient, whose testimonial resonated with attendees.

‍

(Jakarta, Indonesia — December 9, 2025)

‍

Daewoong Indonesia (Daewoong) held a health talk show for 50 dyslipidemia patients at Medistra Hospital as part of its ‘The Lower, The Better’ campaign.

‍

The health talk show held on the 9th at Medistra Hospital, aimed to share the core message of the ‘The Lower, The Better’ campaign—maintaining bad cholesterol (LDL-C) as low as possible to reduce cardiovascular risk—with participating patients. Known as “bad cholesterol,” LDL-C (low-density lipoprotein cholesterol) can build up in blood vessel walls, triggering inflammation and narrowing, and is a key cause of cardiovascular disease.

The seminar was attended by more than 50 participants at the Public Seminar themed “Control LDL, Prevent Heart Disease,” held in Jakarta on December 9, 2025.

‍

Cardiovascular diseases are a leading causes of death in Indonesia. Among cardiovascular disease, stroke, ischemic heart disease, and hypertensive heart disease rank among the country’s top 10 causes of mortality.

‍

According to the Ministry of Health (2021), approximately 800,000 people die from cardiovascular disease in the country each year. In 2021, the WHO (World Health Organization) also reported that three of the top ten causes of death in Indonesia were cardiovascular in nature: stroke (140.8 per 100,000; 2nd), ischemic heart disease (90.4; 3rd), and hypertensive heart disease (20.9; 8th). Given Indonesia’s population of around 286 million, early control and consistent management of key risk factors like dyslipidemia is critically important.

Participants placed stickers and filled out the board provided to assess their initial understanding of the topic, at the seminar themed “Control LDL, Prevent Heart Disease,” held in Jakarta on December 9, 2025.

‍

In her opening remarks, Dr. Stella Melisa, Chief Medical Officer of Daewoong Indonesia, explained the background behind launching the ‘The Lower, The Better’ campaign. She stated “Clinical data show that every 40 mg/dL reduction in LDL‑C lowers cardiovascular risk by approximately 20–25%. Recent ESC (European Society of Cardiology) guidelines also recommend achieving and maintaining LDL‑C levels as low and early as possible.” She continued “With cardiovascular disease claiming nearly 800,000 lives annually in Indonesia, ‘The Lower, The Better’ represents the essential first step in preventing disease among high‑risk patients.”

dr. Stella Melisa, Chief Medical Officer of Daewoong Pharmaceutical Indonesia, explained the background of the launch of the “The Lower, The Better” campaign, based on clinical data showing that every 40 mg/dL reduction in LDL-C can lower cardiovascular risk by approximately 20–25%, and the ESC guideline recommendation to achieve the lowest LDL-C as early as possible, as an important preventive step for high-risk patients in Indonesia, held in Jakarta on December 9, 2025.

‍

On the same day, Dr. dr. Birry Karim, Sp.PD, KKV, a cardiology specialist at Medistra Hospital, educated patients on dyslipidemia and its strong association with cardiovascular disease. He further highlighted current unmet needs, stating “Many dyslipidemia patients still fail to reach the recommended LDL‑C target of under 70 mg/dL, and among very high‑risk patients, less than 10% achieve the 55 mg/dL goal.”

‍

He emphasized that continuous medication adherence is essential for lowering LDL‑C and preventing cardiovascular disease. “The main causes of treatment failure include insufficient statin dosing, muscle-related side effects from high‑intensity statins, and patient‑driven discontinuation,” he said. “Ultimately, sustainable treatment adherence is the foundation of the ‘The Lower, The Better’ strategy.”

Dr. dr. Birry Karim, Sp.PD, KKV, Cardiovascular Specialist from Medistra Hospital, explained that many dyslipidemia patients in Indonesia have not yet achieved their LDL-C targets due to suboptimal therapy intensity and low long-term treatment adherence. He added that combination therapy with ezetimibe and rosuvastatin can lower LDL-C more effectively while improving adherence because the medications are combined into a single tablet, at the Public Seminar themed “Control LDL, Prevent Heart Disease,” held in Jakarta on December 9, 2025.

‍

He also added that dyslipidemia treatment typically begins with statin monotherapy, such as rosuvastatin or atorvastatin. Combination therapy with ezetimibe may be added when LDL-C reduction remains insufficient. From the patient’s perspective, he explained the need for combination therapy as follows: “An ezetimibe–rosuvastatin combination suppresses cholesterol synthesis and absorption simultaneously, offering strong LDL‑C reduction while improving adherence by consolidating two medications into one.” He added, “Considering Indonesia’s low treatment‑continuation rate, the convenience of ‘one pill a day’ can significantly improve both patient quality of life and treatment outcomes.”

Dr. dr. Birry Karim, Sp.PD, KKV, Cardiovascular Specialist from Medistra Hospital, answered questions from participants at the Public Seminar themed “Control LDL, Prevent Heart Disease,” held in Jakarta on December 9, 2025.

‍

Daewoong has launched Indonesia’s first ezetimibe–rosuvastatin combination in a low‑dose 10/5 mg option, along with 10/10 mg and 10/20 mg strengths.This diversified lineup enables tailored prescribing based on individual patient risk, broadening clinical options and supporting long‑term treatment sustainability.

‍

Dr. Adhitya Wardhana, MARS, Director and Hospital President of Medistra Hospital, stated: “This event reinforced Medistra Hospital’s role as a community health partner committed to preventing cardiovascular disease—the leading cause of adult mortality in Indonesia. Through continued collaboration with Daewoong, we aim to further expand patient‑centered education and prevention programs.”

Dr. Adhitya Wardhana, MARS, Director of Medistra Hospital, stated in his opening remarks that the Public Seminar themed “Control LDL, Prevent Heart Disease,” held in Jakarta on December 9, 2025, reinforces Medistra’s role as a community health partner committed to preventing cardiovascular disease, the leading cause of death among adults in Indonesia. He added that through ongoing collaboration with Daewoong, Medistra Hospital will expand patient-focused education and prevention programs.

‍

Meanwhile, Mesya Mohamad (49), a female patient who attended the event, shared her experience: “Today’s health talk was incredibly helpful. The information was thorough—starting from the causes of high cholesterol, its impact, and the proper approaches for treatment and prevention. I learned so many new things. One of the most important is that keeping LDL low is essential. Many of the myths we’ve heard all this time turned out to be incorrect. Through the doctor’s explanation, I now understand which information is accurate and what I need to do moving forward.”

‍

Baik In Hyun, Head of Indonesia Business Division at Daewoong Pharmaceutical and Director of Daewoong Pharmaceutical Indonesia, added: “This health talk show was meaningful as it allowed us to share evidence‑based treatment strategies and preventive messages directly with patients,” he said. “We will continue collaborating with medical institutions like Medistra Hospital to strengthen cardiovascular disease prevention efforts.”

From left to right: Dr. dr. Birry Karim, Sp.PD, KKV, Cardiovascular Specialist from Medistra Hospital; dr. Adhitya Wardhana, MARS, Director of Medistra Hospital; and Mr. Baik In Hyun, Director of Daewoong Pharmaceutical Indonesia, pose for a photo at the Public Seminar themed “Control LDL, Prevent Heart Disease,” held in Jakarta on December 9, 2025.

‍

Medistra Hospital is a premium private hospital located in South Jakarta, offering a wide range of high-quality medical services. With a patient‑centered integrated care system and advanced diagnostic equipment, the hospital is highly capable of treating high‑risk patients. The hospital is also expanding its preventive medicine and health‑screening programs, strengthening its role in community health promotion.

list

- Health talk show held for high‑risk cardiovascular patients, highlighting the importance of LDL‑C control and treatment strategies

- “Lower LDL‑C, better prevention”—addressed causes of treatment failure and introduced combination therapy for sustainable management

- “I thought treatment was finished once I reached my target LDL‑C… but now I realized continuous management is essential,” said one patient, whose testimonial resonated with attendees.

Privacy Policy

이용약관